| Granulomatosis with polyangiitis
Tavneos vs Ruxience
Side-by-side clinical, coverage, and cost comparison for granulomatosis with polyangiitis.Deep comparison between: Tavneos vs Ruxience with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRuxience has a higher rate of injection site reactions vs Tavneos based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ruxience but not Tavneos, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tavneos
Ruxience
At A Glance
Oral
Twice daily
C5aR antagonist
IV infusion
CD20-directed cytolytic antibody
Indications
- Granulomatosis with polyangiitis
- Microscopic Polyarteritis
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Lymphoma, Non-Hodgkin
- Chronic Lymphocytic Leukemia
- Rheumatoid Arthritis
- Granulomatosis with polyangiitis
- Microscopic Polyarteritis
- Pemphigus Vulgaris
Dosing
Granulomatosis with polyangiitis, Microscopic Polyarteritis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 30 mg (three 10 mg capsules) orally twice daily with food; reduce to 30 mg once daily when used concomitantly with strong CYP3A4 inhibitors.
Lymphoma, Non-Hodgkin 375 mg/m2 IV; once weekly for 4 or 8 doses (relapsed/refractory), on Day 1 of each chemotherapy cycle for up to 8 doses (previously untreated follicular or DLBCL), or every 8 weeks for 12 doses as single-agent maintenance.
Chronic Lymphocytic Leukemia 375 mg/m2 IV on Day 1 of Cycle 1, then 500 mg/m2 IV on Day 1 of Cycles 2-6 in combination with fludarabine and cyclophosphamide, every 28 days.
Rheumatoid Arthritis Two 1,000 mg IV infusions separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks, in combination with methotrexate.
Granulomatosis with polyangiitis, Microscopic Polyarteritis Induction: 375 mg/m2 IV once weekly for 4 weeks; follow-up: two 500 mg IV infusions separated by 2 weeks, then 500 mg IV every 6 months based on clinical evaluation, in combination with glucocorticoids.
Pemphigus Vulgaris Two 1,000 mg IV infusions separated by 2 weeks plus tapering glucocorticoids; maintenance: 500 mg IV at Month 12 and every 6 months thereafter; relapse: 1,000 mg IV, no sooner than 16 weeks after the previous infusion.
Contraindications
- Serious hypersensitivity reaction to avacopan or to any of the excipients
—
Adverse Reactions
Most common (>=5%) Nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increased, paresthesia
Serious Pneumonia, GPA, acute kidney injury, urinary tract infection, hepatotoxicity, angioedema
Most common (>=25%) Infusion-related reactions, fever, lymphopenia, chills, infection, asthenia (NHL); infusion-related reactions, neutropenia (CLL).
Serious Infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation with fulminant hepatitis, progressive multifocal leukoencephalopathy, tumor lysis syndrome, infections, cardiovascular adverse reactions, renal toxicity, bowel obstruction and perforation.
Postmarketing Prolonged pancytopenia, marrow hypoplasia, late-onset neutropenia, fatal cardiac failure, uveitis, optic neuritis, systemic vasculitis, pleuritis, lupus-like syndrome, serum sickness, polyarticular arthritis, vasculitis with rash, viral infections including PML, Kaposi's sarcoma progression, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease, PRES/RPLS.
Pharmacology
Avacopan is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a, blocking C5a-mediated neutrophil activation and migration.
Rituximab-pvvr is a chimeric monoclonal antibody that targets the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis through complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tavneos
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Ruxience
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Tavneos
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Ruxience
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Tavneos
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Ruxience
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: ANCA Associated Vasculitis and Granulomatosis with Polyangiitis (formerly Wegeners)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Ruxience Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TavneosView full Tavneos profile
RuxienceView full Ruxience profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.